GAD2 and COVID-19: Antibodies against NMDA receptors (IgG), BDNF (IgG), GAD-65 (IgG), D1 receptor (IgG), and myelin oligodendrocyte glycoprotein (IgG) were elevated in patients with severe COVID-19 and those who required supplemental oxygen compared with those with mild COVID-19.